Скачать или смотреть 🧠 Why Schizophrenia Desperately Needs Better Treatments

Is the standard of care in schizophrenia where it should be?

For decades, psychiatric care for schizophrenia has relied largely on anti-psychotic medications developed in the 1950’s that block dopamine receptors. While these medicines can be effective in alleviating acute psychosis, and are often life-saving, they leave far too many patients struggling with ongoing positive and negative symptoms--along with debilitating side effects.

A recently released medication, Cobenfy, promised to reduce side effect burden by targeting muscarinic receptors in the brain rather than dopamine receptors. Cobenfy is actually a combination of two drugs: a muscarinic antagonist that targets dopamine activity indirectly, and a second drug to manage peripheral side effects caused by the muscarinic action. A closer look at the clinical trials leading to the drug’s approval, however, have many in the psychiatric community questioning whether this drug will live up to promises:

   • Cobenfy (KarXT): A new miracle drug for sc...  

Meanwhile, clinical trials and anecdotal reports are shining a light on ketogenic and other metabolic therapies as a novel adjunctive or even primary treatment for schizophrenia.

As World Schizophrenia Day approaches, we’re focusing on this often-overlooked condition, why the status quo isn’t good enough, and how readily available ketogenic and metabolic therapies might offer new hope.

#WorldSchizophreniaDay